Compare Stocks: LRMR, ANAB, VIR, and ABSI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$9.09 -3.5%	$9.29	$2.24 ▼ $12.06	$1.56B	2.35	4.39 million shs	220,982 shs
ANAB AnaptysBio	$56.64 -1.1%	$58.57	$11.40 ▼ $72.36	$1.68B	0.72	708,935 shs	17,182 shs
LRMR Larimar Therapeutics	$4.05	$3.86	$2.71 ▼ $6.42	$420.71M	0.81	2.69 million shs	37,585 shs
VIR Vir Biotechnology	$11.41 +0.9%	$9.56	$4.75 ▼ $11.66	$1.93B	1.66	2.44 million shs	114,585 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+2.17%	+1.51%	+32.12%	+39.56%	+269.41%
ANAB AnaptysBio	-1.22%	+1.06%	+9.94%	+2.91%	+180.83%
LRMR Larimar Therapeutics	-2.88%	-2.64%	+5.74%	+16.38%	+3.85%
VIR Vir Biotechnology	+2.08%	+22.80%	+27.80%	+18.55%	+116.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$9.09 -3.5%	$9.29	$2.24 ▼ $12.06	$1.56B	2.35	4.39 million shs	220,982 shs
ANAB AnaptysBio	$56.64 -1.1%	$58.57	$11.40 ▼ $72.36	$1.68B	0.72	708,935 shs	17,182 shs
LRMR Larimar Therapeutics	$4.05	$3.86	$2.71 ▼ $6.42	$420.71M	0.81	2.69 million shs	37,585 shs
VIR Vir Biotechnology	$11.41 +0.9%	$9.56	$4.75 ▼ $11.66	$1.93B	1.66	2.44 million shs	114,585 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+2.17%	+1.51%	+32.12%	+39.56%	+269.41%
ANAB AnaptysBio	-1.22%	+1.06%	+9.94%	+2.91%	+180.83%
LRMR Larimar Therapeutics	-2.88%	-2.64%	+5.74%	+16.38%	+3.85%
VIR Vir Biotechnology	+2.08%	+22.80%	+27.80%	+18.55%	+116.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.78	Moderate Buy	$13.43	42.55% Upside
ANAB AnaptysBio	2.64	Moderate Buy	$80.00	39.64% Upside
LRMR Larimar Therapeutics	3.10	Buy	$11.67	188.07% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$21.57	90.73% Upside

Current Analyst Ratings Breakdown

Latest LRMR, ANAB, VIR, and ABSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	ANAB AnaptysBio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$75.00 ➝ $70.00
8/25/2026	ANAB AnaptysBio	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold	$70.00
8/24/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
8/12/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/12/2026	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/10/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	ANAB AnaptysBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/6/2026	VIR Vir Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
7/17/2026	ABSI Absci	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$1.56M	1,035.62	N/A	N/A	$1.43 per share	6.59
ANAB AnaptysBio	$234.60M	7.23	N/A	N/A	$1.34 per share	42.75
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.23 per share	N/A
VIR Vir Biotechnology	$68.56M	27.92	N/A	N/A	$5.81 per share	1.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.80	N/A	N/A	N/A	-7,756.38%	-61.71%	-54.52%	11/16/2026 (Estimated)
ANAB AnaptysBio	-$13.23M	-$1.08	N/A	17.63	N/A	-11.53%	N/A	-7.75%	11/10/2026 (Estimated)
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	-638.88%	-29.99%	-23.62%	11/4/2026 (Estimated)

Latest LRMR, ANAB, VIR, and ABSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ABSI Absci	-$0.1910	-$0.21	-$0.0190	-$0.21	$0.92 million	$0.32 million
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	10.63	10.63
ANAB AnaptysBio	N/A	7.58	7.58
LRMR Larimar Therapeutics	N/A	4.70	4.70
VIR Vir Biotechnology	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
ANAB AnaptysBio	N/A
LRMR Larimar Therapeutics	91.92%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
ANAB AnaptysBio	31.50%
LRMR Larimar Therapeutics	4.00%
VIR Vir Biotechnology	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	210	171.61 million	153.56 million	Optionable
ANAB AnaptysBio	100	29.61 million	20.28 million	Optionable
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable
VIR Vir Biotechnology	580	169.22 million	164.31 million	Optionable

LRMR, ANAB, VIR, and ABSI Headlines

Recent News About These Companies

BlackRock Inc. Purchases New Position in Vir Biotechnology, Inc. $VIR

August 28 at 3:36 AM | marketbeat.com

Vir Biotechnology, Inc. (VIR) Stock Price, News, Quote & History - Yahoo Finance

August 28 at 1:51 AM | finance.yahoo.com

Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR

August 27 at 3:20 AM | marketbeat.com

ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR

August 26 at 3:19 AM | marketbeat.com

ARCH Venture Management LLC Invests $129.35 Billion in Vir Biotechnology, Inc. $VIR

August 26 at 3:11 AM | marketbeat.com

Vir Biotechnology climbs 9% amid post-earnings uptrend

August 25 at 7:37 PM | seekingalpha.com

Vir Biotechnology (NASDAQ:VIR) Shares Up 8.1% - Time to Buy?

August 25 at 11:59 AM | marketbeat.com

Parkman Healthcare Partners LLC Takes Position in Vir Biotechnology, Inc. $VIR

August 25 at 6:40 AM | marketbeat.com

Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum

August 20, 2026 | theglobeandmail.com

Vir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst

August 19, 2026 | tipranks.com

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

Equities Analysts Offer Predictions for VIR Q3 Earnings

August 12, 2026 | marketbeat.com

Vir Biotechnology (VIR) Receives a Buy from Bank of America Securities

August 12, 2026 | theglobeandmail.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 11, 2026 | marketbeat.com

Evercore ISI Sticks to Its Buy Rating for Vir Biotechnology (VIR)

August 9, 2026 | theglobeandmail.com

Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary

August 7, 2026 | finance.yahoo.com

Vir outlines ECLIPSE 1 top-line in Q4 2026 while projecting cash runway into the second half of 2028

August 6, 2026 | seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Vir Biotechnology Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

August 5, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LRMR, ANAB, VIR, and ABSI Company Descriptions

Absci NASDAQ:ABSI

$9.09 -0.33 (-3.50%)

As of 09:52 AM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

AnaptysBio NASDAQ:ANAB

$56.64 -0.65 (-1.13%)

As of 09:49 AM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Larimar Therapeutics NASDAQ:LRMR

$4.05 0.00 (0.00%)

As of 09:51 AM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Vir Biotechnology NASDAQ:VIR

$11.41 +0.10 (+0.88%)

As of 09:52 AM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LRMR, ANAB, VIR, and ABSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LRMR, ANAB, VIR, and ABSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LRMR, ANAB, VIR, and ABSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LRMR, ANAB, VIR, and ABSI Company Descriptions

Absci NASDAQ:ABSI

AnaptysBio NASDAQ:ANAB

Larimar Therapeutics NASDAQ:LRMR

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LRMR, ANAB, VIR, and ABSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LRMR, ANAB, VIR, and ABSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LRMR, ANAB, VIR, and ABSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LRMR, ANAB, VIR, and ABSI Company Descriptions

Absci NASDAQ:ABSI

AnaptysBio NASDAQ:ANAB

Larimar Therapeutics NASDAQ:LRMR

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools